ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis.

Brandon Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.